Lung cancer and positron emission tomography with fluorodeoxyglucose

Edith M. Marom; Jeremy J. Erasmus; Edward F. Patz

doi:10.1016/S0169-5002(00)00096-9

Lung cancer and positron emission tomography with fluorodeoxyglucose

Edith M. Marom, Jeremy J. Erasmus, Edward F. Patz

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

Over the past years, positron emission tomography (PET) with fluoro-2- deoxy-D-glucose (FDG) has emerged as an important imaging modality. In the thorax, FDG-PET has been shown to differentiate benign from malignant pulmonary lesions and stage lung cancer. Preliminary studies have shown its usefulness in assessing tumor recurrence, and assisting in radiotherapy planning. FDG-PET is often more accurate than conventional imaging studies, and has been proven to be cost-effective in evaluating lung cancer patients. This review will discuss the current applications of FDG-PET as compared with conventional imaging in diagnosing, staging, and following patients with lung cancer. (C) 2000 Elsevier Science Ireland Ltd.

Original language	English (US)
Pages (from-to)	187-202
Number of pages	16
Journal	Lung Cancer
Volume	28
Issue number	3
DOIs	https://doi.org/10.1016/S0169-5002(00)00096-9
State	Published - Jun 2000
Externally published	Yes

Keywords

Diagnosis
Lung cancer
Positron emission tomography
Prognosis
Staging
Treatment

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

Access to Document

10.1016/S0169-5002(00)00096-9

Cite this

@article{1e75636f517b4c7c93cedaf01050857a,

title = "Lung cancer and positron emission tomography with fluorodeoxyglucose",

abstract = "Over the past years, positron emission tomography (PET) with fluoro-2- deoxy-D-glucose (FDG) has emerged as an important imaging modality. In the thorax, FDG-PET has been shown to differentiate benign from malignant pulmonary lesions and stage lung cancer. Preliminary studies have shown its usefulness in assessing tumor recurrence, and assisting in radiotherapy planning. FDG-PET is often more accurate than conventional imaging studies, and has been proven to be cost-effective in evaluating lung cancer patients. This review will discuss the current applications of FDG-PET as compared with conventional imaging in diagnosing, staging, and following patients with lung cancer. (C) 2000 Elsevier Science Ireland Ltd.",

keywords = "Diagnosis, Lung cancer, Positron emission tomography, Prognosis, Staging, Treatment",

author = "Marom, {Edith M.} and Erasmus, {Jeremy J.} and Patz, {Edward F.}",

year = "2000",

month = jun,

doi = "10.1016/S0169-5002(00)00096-9",

language = "English (US)",

volume = "28",

pages = "187--202",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

number = "3",

}

TY - JOUR

T1 - Lung cancer and positron emission tomography with fluorodeoxyglucose

AU - Marom, Edith M.

AU - Erasmus, Jeremy J.

AU - Patz, Edward F.

PY - 2000/6

Y1 - 2000/6

N2 - Over the past years, positron emission tomography (PET) with fluoro-2- deoxy-D-glucose (FDG) has emerged as an important imaging modality. In the thorax, FDG-PET has been shown to differentiate benign from malignant pulmonary lesions and stage lung cancer. Preliminary studies have shown its usefulness in assessing tumor recurrence, and assisting in radiotherapy planning. FDG-PET is often more accurate than conventional imaging studies, and has been proven to be cost-effective in evaluating lung cancer patients. This review will discuss the current applications of FDG-PET as compared with conventional imaging in diagnosing, staging, and following patients with lung cancer. (C) 2000 Elsevier Science Ireland Ltd.

AB - Over the past years, positron emission tomography (PET) with fluoro-2- deoxy-D-glucose (FDG) has emerged as an important imaging modality. In the thorax, FDG-PET has been shown to differentiate benign from malignant pulmonary lesions and stage lung cancer. Preliminary studies have shown its usefulness in assessing tumor recurrence, and assisting in radiotherapy planning. FDG-PET is often more accurate than conventional imaging studies, and has been proven to be cost-effective in evaluating lung cancer patients. This review will discuss the current applications of FDG-PET as compared with conventional imaging in diagnosing, staging, and following patients with lung cancer. (C) 2000 Elsevier Science Ireland Ltd.

KW - Diagnosis

KW - Lung cancer

KW - Positron emission tomography

KW - Prognosis

KW - Staging

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0034016999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034016999&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(00)00096-9

DO - 10.1016/S0169-5002(00)00096-9

M3 - Article

C2 - 10812188

AN - SCOPUS:0034016999

SN - 0169-5002

VL - 28

SP - 187

EP - 202

JO - Lung Cancer

JF - Lung Cancer

IS - 3

ER -

Lung cancer and positron emission tomography with fluorodeoxyglucose

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this